데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
98631-95-9CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=OOCOKWVBYZHBHLU-UHFFFAOYSA-N98631-95-9DTXSID5045203CHEMBL1256871CHEBI:32136안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요Sobuzoxane, a novel bis(2,6-dioxopiperazine) derivative, was introduced in Japan for the treatment of malignant lymphoma and adult T-cell IeukemiaQmphoma (ATLL), which is resistant to chemotherapy and has a poor prognosis. Sobuzoxane exhibits 8 broad spectrum of antitumor activity. It is a noncleavable complexstabilizing topoisomerase II inhibitor and exerts its function via interfering with the catalytic activity of the enzyme to result in an irreversible inhibition of cell division by blockade of chromosome condensation and segregation. Due to Its unique mode of cytocidai activity, it has no cross resistance with many currently available anticancer agents. Sobuzoxane is reported to significantly inhibit growth of human colon, lung, gastric, and breast cancers and is in clinical trials for these indications.
용도Sobuzoxane is an inhibitor of DNA topoisomerase II which induces apoptosis.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…